MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2

Clinical and Experimental Metastasis

Volumn 24, Issue 5, 2007, Pages 341-351

  Mendes, Odete ^a   Kim, Hun Taek ^a   Lungu, Gina ^a   Stoica, George ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Brain metastases; Breast cancer; ERK1 2; MAPK; MMP2; TIMP2

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GELATINASE A; GLIAL FIBRILLARY ACIDIC PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN METASTASIS; BREAST ADENOCARCINOMA; CANCER GROWTH; CARCINOMA CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENETIC TRANSFECTION; INOCULATION; NERVE CELL CULTURE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; FEMALE; FLAVONOIDS; GLIAL FIBRILLARY ACIDIC PROTEIN; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RATS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 34547183458     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9071-0     Document Type: Article

References (51)

1. Nishizuka I, Ishikawa T et al (2002) Analysis of gene expression involved in brain metastases from breast cancer using cDNA microarray. Breast Cancer 9(1):26-32
2. Jaalinoja J, Herva R et al (2000) Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 46(1):81-90
3. Arnold SM, Young AB et al (1999) Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastases. Clin Cancer Res 5(12):4028-4033
4. Mendes O, Kim HT, Stoica G (2005) Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 22(3):237-246
5. Hall DG, Stoica G (1994) Characterization of brain and bone-metastasizing clones selected from an ethylnitrosurea-induced rat mammary carcinoma. Clin Exp Metastasis 12(4):283-295
6. Leppa S, Saarto T, Vehmanen L et al (2004) High serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10(3):1057-1063
7. Duffy MJ, Maguire TM et al (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastases. Breast Cancer Res 2(4):252-257 (Epub 2000 Jun 7)
8. Danilewicz M, Sikorska B, Wagrowska-Danilewicz M (2003) Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer. Med Sci Monit 9(3):MT42-MT47
9. Kazes I, Elalamy I, Sraer JD et al (2000) Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 96(9):3064-3069
10. Gakiopoulou H, Nakopoulou L, Siatelis A et al (2003) Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 9(15):5573-5581
11. Remacle A, McCarthy K, Noel A et al (2000) High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 89(2):118-121
12. Visscher DW, Hoyhtya M, Ottosen SK et al (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59(3):339-344
13. Zhao YG, Xiao AZ, Park HI et al (2004) Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res 64(2):590-598
14. Li H, Lindenmeyer F, Grenet C et al (2001) AdTIMP-2 inhibits tumor growth, angiogenesis, and metastases, and prolongs survival in mice. Hum Gene Ther 12(5):515-526
15. Liuzzi GM, Mastroianni CM, Latronico T et al (2004) Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127(Pt 2):398-407 (Epub 2003 Dec 8)
16. Massengale JL, Gasche Y, Chan PH (2002) Carbohydrate source influences gelatinase production by mouse astrocytes in vitro. Glia 38(3):240-245
17. Rosenberg GA, Cunningham LA, Wallace J et al (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893(1-2):104-112
18. Giraudon P, Szymocha R, Buart S et al (2000) T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease. J Immunol 164(5):2718-2727
19. Nagashima G, Suzuki R, Asai J et al (2002) Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg 104(2):125-131
20. Levicar N, Nuttall RK, Lah TT (2003) Proteases in brain tumour progression. Acta Neurochir (Wien) 145(9):825-838
21. Nuttall RK, Pennington CJ, Taplin J et al (2003) Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 1(5):333-345
22. Le DM, Besson A, Fogg DK et al (2003) Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 23(10):4034-4043
23. Leveque T, Le Pavec G, Boutet A et al (2004) Differential regulation of gelatinase A and B and TIMP-1 and -2 by TNFalpha and HIV virions in astrocytes. Microbes Infect 6(2):157-163
24. Muir EM, Adcock KH, Morgenstern DA et al (2002) Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 100(1-2):103-117
25. Arai K, Lee SR, Lo EH (2004) Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 43(3):254-264
26. Lee WJ, Shin CY, Yoo BK et al (2003) Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41(1):15-24
27. Sierra A, Price JE, Garcia-Ramirez M et al (1997) Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest 77(4):357-368
28. Alessandrini A (2002) The roles of map kinases in controlling cancer metastases. In: Welch DR (ed) Cancer metastases-related genes, vol 3. Kluwer, Boston, pp 35-51
29. Christopherson KS, Ullian EM, Stokes CC et al (2005) Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120(3):421-433
30. Venugopal SK, Devaraj S, Jialal I (2005) Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 166(4):1265-1271
31. Lu W, Zhou X, Hong B et al (2004) Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP-2 and PTEN gene. Cancer Lett 214(2):205-213
32. Forough R, Lea H, Starcher B et al (1998) Metalloproteinase blockade by local overexpression of TIMP-1 increases elastin accumulation in rat carotid artery intima. Arterioscler Thromb Vasc Biol 18(5):803-807
33. Kai HS, Butler GS, Morrison CJ et al (2002) Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain. J Biol Chem 277(50):48696-48707 (Epub 2002 Oct 8)
34. Lee PP, Hwang JJ, Murphy G et al (2000) Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology 141(10):3764-3773
35. Scott KA, Holdsworth H, Balkwill FR et al (2000) Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model. Br J Cancer 83(11):1538-1543
36. Tester AM, Waltham M, Oh SJ et al (2004) Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastases of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 64(2):652-658
37. Hanemaaijer R, Verheijen JH, Maguire TM et al (2000) Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 86(2):204-207
38. Xie TX, Huang FJ, Aldape KD et al (2006) Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66(6):3188-3196
39. Yoneda T (2000) Cellular and molecular basis of preferential metastases of breast cancer to bone. J Orthop Sci 5(1):75-81
40. Rolli M, Fransvea E, Pilch J et al (2003) Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 100(16):9482-9487 (Epub 2003 Jul 21)
41. Saad S, Bendall LJ, James A et al (2000) Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Res Treat 63(2):105-115
42. Wang M, Liu YE, Greene J et al (1997) Inhibition of tumor growth and metastases of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14(23):2767-2774
43. Thorgeirsson UP, Yoshiji H et al (1996) Breast cancer; tumor neovasculature and the effect of tissue inhibitor of metalloproteinases-1 (TIMP-1) on angiogenesis. In Vivo 10(2):137-144
44. Kawamata H, Kawai K, Kameyama S et al (1995) Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastases of a rat bladder carcinoma. Int J Cancer 63(5):680-687
45. Ahn SM, Jeong SJ, Kim YS et al (2004) Retroviral delivery of TIMP-2 inhibits H-RAS-induced migration and invasion in MCF10A human breast epithelial cells. Cancer Lett 207(1):49-57
46. Kim MS, Lee EJ, Kim HR et al (2003) p38 kinase is a key signaling molecule for H-RAS-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 63(17):5454-5461
47. Liu JF, Crepin M, Liu JM et al (2002) FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the RAS/ERK pathway. Biochem Biophys Res Commun 293(4):1174-1182
48. Pan MR, Hung WC (2002) Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 277(36):32775-32780 (Epub 2002 Jun 26)
49. Tanimura S, Asato K, Fujishiro SH et al (2003) Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun 304(4):801-806
50. Fromigue O, Louis K, Wu E et al (2003) Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase. Int J Cancer 106(3):355-363
51. Utani A, Momota Y, Endo H et al (2003) Laminin alpha 3 LG4 module induces matrix metalloproteinase-1 through mitogen-activated protein kinase signaling. J Biol Chem 278(36):34483-34490 (Epub 2003 Jun 24)